AGÕæÈ˹ٷ½

STOCK TITAN

[SCHEDULE 13G] Vivos Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentage is calculated based upon (i) 5,889,520 shares of Common Stock issued and outstanding as of May 15, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the SEC on May 15, 2025, plus (ii) 828,000 shares of Common Stock issued to V-Co Investors 2 LLC on June 9, 2025 in connection with a private financing between V-Co Investors 2 LLC and the Company.


SCHEDULE 13G



Dawei Luo
Signature:/s/ Dawei Luo
Name/Title:Dawei Luo
Date:07/14/2025
Vivos Therapeutics Inc

NASDAQ:VVOS

VVOS Rankings

VVOS Latest News

VVOS Latest SEC Filings

VVOS Stock Data

24.21M
3.67M
32.99%
10.76%
4.28%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States
LITTLETON